Development and Validation of a Digital Optotype for Near Vision in Greek Language. (DeDART)

January 24, 2020 updated by: Georgios Labiris, Democritus University of Thrace

Development and Validation of a Computer-based Digital Near-vision Optotype Based on the Greek Version of the Print MNREAD.

Primary objective of our study is to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Present study aims to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.

Specifically, it aims to evaluate the level of agreement between the conventional printed greek MNREAD chart and the corresponding digital chart, as well as test-retest reliability of the digital optotype.

To address these aims, four reading parameters measured with the print and the digital version are compared. These parameters are the following:

  1. Reading Acuity (RA)
  2. Maximum Reading Speed (MRS)
  3. Critical Print Size (CPS)
  4. Accessibility Index (ACC)

All the comparisons take place in two groups: a) a Normal Vision Group (NVG), and b) a Low Vision Group (LVG) in order to estimate the reading capacity in a population with a wide range of vision.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Evros
      • Alexandroupolis, Evros, Greece, 68100
        • University Hospital of Alexandroupolis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 73 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Normal- and low-sighted participants aged 18 to 75 years

Description

Inclusion Criteria:

  • adequate literacy of written Greek language

Exclusion Criteria:

  • dyslexia
  • attention-deficiency
  • former diagnosis of mental diseases
  • former diagnosis of psychiatric diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control group
  1. 70 patients with normal vision (NVG) with adequate literacy of written Greek language
  2. 30 patients with low vision (LVG) with adequate literacy of written Greek language

These patients are tested on the printed Greek MNREAD

One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
Study group
The same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reading Acuity (RA)
Time Frame: through study completion, an average of 8 months

The smallest print that the patient can read without making significant errors, and can be calculated by the following formula:

Acuity (in logMAR)= 1.4 - (sentences x 0.1) + (errors x 0.01).

through study completion, an average of 8 months
Maximum Reading Speed (MRS)
Time Frame: through study completion, an average of 8 months
The patient's reading speed when reading is not limited by print size , and is calculated by averaging the speed of the sentences with print size larger than the CPS. [(in words per minute (wpm)]
through study completion, an average of 8 months
Critical Print Size (CPS)
Time Frame: through study completion, an average of 8 months
The smallest print size at which patients can read with their MRS, and is identified as the print size of the sentence fulfilling this criterion: all of the following sentences are read at a speed that is 1.96 times the standard deviation below the average of the larger preceding sentences (that is the MRS). In other words, it is defined as the smallest print size that yields 90% of the MRS [(in logMAR)]
through study completion, an average of 8 months
Accessibility Index (ACC)
Time Frame: through study completion, an average of 8 months
The mean reading speed measured across the 10 largest print sizes (1.3 to 0.4 logMAR) of the MNREAD Acuity Chart at 40 cm normalized by 200 wpm, which was the mean value for a group of 365 normally sighted young adults aged 18 to 39 years old.
through study completion, an average of 8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraclass Correlation Coefficients (ICCs) for study participants
Time Frame: through study completion, an average of 8 months
Level of agreement between the print and the digital version are evaluated by calculation of the ICCs for the 4 reading parameters (RA, MRS, CPS, ACC).
through study completion, an average of 8 months
Test-retest Intraclass Correlation Coefficients (ICCs)
Time Frame: through study completion, an average of 8 months
Test-retest reliability of the digital optotype is evaluated by ICCs for the 4 reading parameters (RA, MRS, CPS, ACC)..
through study completion, an average of 8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Georgios Labiris, MD, PhD, University Hospital of Alexandroupolis, Alexandroupolis, Greece

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 28, 2019

Primary Completion (Actual)

June 28, 2019

Study Completion (Actual)

November 28, 2019

Study Registration Dates

First Submitted

January 8, 2020

First Submitted That Met QC Criteria

January 24, 2020

First Posted (Actual)

January 27, 2020

Study Record Updates

Last Update Posted (Actual)

January 27, 2020

Last Update Submitted That Met QC Criteria

January 24, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Presbyopia

Clinical Trials on MNREAD testing

3
Subscribe